Amneal Pharmaceuticals (AMRX) Change in Accured Expenses (2017 - 2026)

Amneal Pharmaceuticals' Change in Accured Expenses history runs 10 years deep, the most recent figure standing at -$124.6 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 10.61% year-over-year to -$124.6 million in Q1 2026; TTM through Mar 2026 was $9.4 million, a 84.47% decrease from a year earlier, with the FY2025 full-year figure at $21.3 million, down 90.93% from the prior year.
• Change in Accured Expenses declined to -$124.6 million in Q1 2026 per AMRX's latest filing, from $18.6 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $322.7 million in Q2 2022 and bottomed at -$150.5 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $33.1 million (2023), against an average of $8.6 million.
• Biggest YoY gain for Change in Accured Expenses was 1905.87% in 2022; the steepest drop was 828.86% in 2022.
• Year by year, Change in Accured Expenses stood at -$55.9 million in 2022, then soared by 64.63% to -$19.8 million in 2023, then soared by 435.29% to $66.3 million in 2024, then tumbled by 71.96% to $18.6 million in 2025, then slumped by 770.6% to -$124.6 million in 2026.
• Per Business Quant, the three latest AMRX Change in Accured Expenses figures stand at -$124.6 million (Q1 2026), $18.6 million (Q4 2025), and $69.7 million (Q3 2025).